Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual...
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation...
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office...
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike...
FERRETTI INTERNATIONAL HOLDING S.P.A. EXPRESSES NO INTENTION TO SUPPORT THE PARTIAL PUBLIC TENDER OFFER LAUNCHED BY KKCG MARITIME
REAFFIRMS ITS LONG-TERM INVESTMENT IN THE COMPANY AND CONFIRMS ITS INTENTION TO NOMINATE THE MAJORITY OF THE DIRECTORS OF FERRETTI S.P.A. MILAN, Jan. 22, 2026 /PRNewswire/ -- Ferretti International Holding S.p.A. ("FIH"), as the controlling...